The estimated Net Worth of Helen Sabzevari is at least $4.32 Million dollars as of 5 April 2024. Dr Sabzevari owns over 1,071,429 units of Precigen Inc stock worth over $2,552,490 and over the last 7 years he sold PGEN stock worth over $0. In addition, he makes $1,765,316 as Pres und CEO & Director at Precigen Inc.
Dr has made over 23 trades of the Precigen Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 1,071,429 units of PGEN stock worth $1,039,286 on 5 April 2024.
The largest trade he's ever made was exercising 1,071,429 units of Precigen Inc stock on 5 April 2024 worth over $1,039,286. On average, Dr trades about 70,098 units every 32 days since 2018. As of 5 April 2024 he still owns at least 2,631,433 units of Precigen Inc stock.
You can see the complete history of Dr Sabzevari stock trades at the bottom of the page.
Dr. Helen Sabzevari MPH, Ph.D. is the Pres, CEO & Director at Precigen Inc.
As the Pres und CEO & Director of Precigen Inc, the total compensation of Dr D at Precigen Inc is $1,765,316. There are 1 executives at Precigen Inc getting paid more, with Randal Kirk having the highest compensation of $2,067,620.
Dr D is 59, he's been the Pres und CEO & Director of Precigen Inc since . There are 9 older and 9 younger executives at Precigen Inc. The oldest executive at Precigen Inc is Robert Shapiro, 81, who is the Lead Independent Director.
Over the last 5 years, insiders at Precigen Inc have traded over $44,216,787 worth of Precigen Inc stock and bought 52,689,457 units worth $114,197,137 . The most active insiders traders include Randal J Kirk, Trading S.A. Ares und Helen Sabzevari. On average, Precigen Inc executives and independent directors trade stock every 9 days with the average trade being worth of $358,866. The most recent stock trade was executed by Randal J Kirk on 9 August 2024, trading 23,529,411 units of PGEN stock currently worth $19,999,999.
precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua
Precigen Inc executives and other stock owners filed with the SEC include: